PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 2, 2013, Pages 365-374

  Foot, Jonathan S ^a   Yow, Tin T ^a   Schilter, Heidi ^a   Buson, Alberto ^a   Deodhar, Mandar ^a   Findlay, Alison D ^a   Guo, Lily ^a   McDonald, Ian A ^a   Turner, Craig I ^a   Zhou, Wenbin ^a   Jarolimek, Wolfgang ^a  

^a Pharmaxis Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 METHYLHYDRAZINYL) 2,3 DIHYDRO 1H INDEN 1 OL; 3 FLUORO 2 (4 METHOXYBENZYL)ALLYLAMINE; 4 [2 (AMINOMETHYL) 3 FLUOROALLYL]BENZENESULFONAMIDE; AMINE OXIDASE (COPPER CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING); ANTIINFLAMMATORY AGENT; BTT 2052; CARRAGEENAN; DEXAMETHASONE; INTERLEUKIN 6; ION CHANNEL; LIPOPOLYSACCHARIDE; LJP 1207; LJP 1586; MEMBRANE PROTEIN; MOFEGILINE; MONOAMINE OXIDASE INHIBITOR; N' (2 PHENYLALLYL)HYDRAZINE; PXS 4159A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1;

ABDOMINAL FAT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DERMATITIS; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; RESPIRATORY TRACT INFLAMMATION;

ADIPOSE TISSUE; ALLYL COMPOUNDS; AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL ADHESION MOLECULES; DERMATITIS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MICE; MICROSOMES; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PNEUMONIA; RABBITS; RATS; SMALL MOLECULE LIBRARIES; SPECIES SPECIFICITY; SULFONAMIDES;

EID: 84885979004     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.207613     Document Type: Article

References (46)

1. Aalto K, Maksimow M, Juonala M., Viikari J, Jula A, Kähönen M, Jalkanen S, Raitakari OT, and Salmi M (2012) Soluble vascular adhesion protein-1 correlates with cardiovascular risk factors and early atherosclerotic manifestations. Arterioscler Thromb Vasc Biol 32:523-532.
2. Andrés N., Lizcano JM, Rodríguez MJ, Romera M., Unzeta M, and Mahy N (2001) Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase. J Histochem Cytochem 49:209-217.
3. Biollaz J, Munafo A, Buclin T., Gervasoni JP, Magnin JL, Jaquet F, and Brunner-Ferber F (1995) Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 47:455-460.
4. Boomsma F, van den Meiracker AH, Winkel S, Aanstoot HJ, Batstra MR, Man in 't Veld AJ, and Bruining GJ (1999) Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis. Diabetologia 42:233-237.
5. Bowes J, Brown AJ, Hamon J, Jarolimek W.J., Sridhar A., Waldron G, and Whitebread S (2012) Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov 11:909-922.
6. Corteling R, Wyss D, and Trifilieff A (2002) In vivo models of lung neutrophil activation. Comparison of mice and hamsters. BMC Pharmacol 2:1.
7. Dunkel P, Balogh B, Meleddu R., Maccioni E, Gyires K, and Mátyus P (2011) Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey. Expert Opin Ther Pat 21:1453-1471.
8. Elliott J, Callingham BA, and Barrand MA (1989) In-vivo effects of (E)-2-(3',4'-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat. Selective inhibition of semicarbazide-sensitive amine oxidase in vascular and brown adipose tissues. J Pharm Pharmacol 41:37-41.
9. Ferjancic S, Gil-Bernabé AM, Hill SA, Allen PD, Richardson P, Sparey T, Savory E, McGuffog J, and Muschel RJ (2013) VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice. Blood 121:3289-3297.
10. Foot JS, Deodhar M, Turner C.I., Yin P., van Dam EM, Silva DG, Olivieri A, Holt A, and McDonald IA (2012) The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1). Bioorg Med Chem Lett 22:3935-3940.
11. Green JP, Prell GD, Khandelwal J.K., and Blandina P (1987) Aspects of histamine metabolism. Agents Actions 22:1-15.
12. Holt A, Smith DJ, Cendron L, Zanotti G., Rigo A, and Di Paolo ML (2008) Multiple binding sites for substrates and modulators of semicarbazide-sensitive amine oxidases: kinetic consequences. Mol Pharmacol 73:525-538.
13. Holt A and Palcic MM (2006) A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes. Nat Protoc 1:2498-2505.
14. Imamura Y, Kubota R, Wang Y., Asakawa S, Kudoh J, Mashima Y., Oguchi Y, and Shimizu N (1997) Human retina-specific amine oxidase (RAO): cDNA cloning, tissue expression, and chromosomal mapping. Genomics 40:277-283.
15. Inoue T, Morita M, Tojo T., Yoshihara K, Nagashima A, Moritomo A., Ohkubo M, and Miyake H (2013a) Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema. Bioorg Med Chem 21:1219-1233.
16. Inoue T, Morita M, Tojo T., Nagashima A, Moritomo A, Imai K., and Miyake H (2013b) Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: part 2. Bioorg Med Chem 21:2478-2494.
17. Inoue T, Morita M, Tojo T., Nagashima A, Moritomo A, and Miyake H (2013c) Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment. Bioorg Med Chem 21:3873-3881.
18. Jalkanen S, Karikoski M, Mercier N., Koskinen K, Henttinen T, Elima K., Salmivirta K, and Salmi M (2007) The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding. Blood 110: 1864-1870.
19. Kaitaniemi S, Elovaara H, Grön K, Kidron H., Liukkonen J, Salminen T, Salmi M., Jalkanen S, and Elima K (2009) The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci 66:2743-2757.
20. Kitz R and Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245-3249.
21. Kurkijärvi R., Adams DH, Leino R, Möttönen T, Jalkanen S, and Salmi M (1998) Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 161:1549-1557.
22. Kurkijärvi R., Jalkanen S, Isoniemi H., and Salmi M (2001) Vascular adhesion protein-1 (VAP-1) mediates lymphocyte-endothelial interactions in chronic kidney rejection. Eur J Immunol 31:2876-2884.
23. Kurkijärvi R., Yegutkin GG, Gunson B.K., Jalkanen S., Salmi M, and Adams DH (2000) Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology 119: 1096-1103.
24. Lalor PF, Sun PJ, Weston C.J., Martin-Santos A, Wakelam MJO, and Adams DH (2007) Activation of vascular adhesion protein-1 on liver endothelium results in an NF-kappaB-dependent increase in lymphocyte adhesion. Hepatology 45:465-474.
25. Li HY, Wei JN, Lin M.S., Smith DJ, Vainio J, Lin CH, Chiang F.T., Shih SR, Huang CH, and Wu MY, et al. (2009) Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia. Clin Chim Acta 404:149-153.
26. Li HY, Jiang YD, Chang T.J., Wei JN, Lin MS, Lin CH, Chiang F.T., Shih SR, Hung CS, and Hua CH, et al. (2011) Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes. Diabetes 60:993-999.
27. Lin MS, Li HY, Wei J.N., Lin CH, Smith DJ, Vainio J, Shih S.R., Chen YH, Lin LC, and Kao HL, et al. (2008) Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clin Biochem 41:1362-1367.
28. Lyles GA and Chalmers J (1992) The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem Pharmacol 43:1409-1414.
29. McDonald IA, Foot JS, Yin P, Fleming E., and van Dam EM (2007) Semicarbazide-sensitive amine oxidase and vascular adhesion protein-1: One protein being validated as a therapeutic target for inflammatory diseases. Annu Rep Med Chem 42:229-243.
30. Morin N, Lizcano JM, Fontana E, Marti L., Smih F, Rouet P, Prévot D, Zorzano A., Unzeta M, and Carpéné C (2001) Semicarbazide- sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes. J Pharmacol Exp Ther 297:563-572.
31. O'Rourke A.M., Wang EY, Miller A, Podar E.M., Scheyhing K., Huang L, Kessler C, Gao H., Ton-Nu HT, and Macdonald MT, et al. (2008) Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. J Pharmacol Exp Ther 324:867-875.
32. O'Sullivan J., Unzeta M, Healy J., O'Sullivan MI, Davey G, and Tipton KF (2004) Semicarbazide-sensitive amine oxidases: enzymes with quite a lot to do. Neurotoxicology 25:303-315.
33. Precious E, Gunn CE, and Lyles GA (1988) Deamination of methylamine by semicarbazide-sensitive amine oxidase in human umbilical artery and rat aorta. Biochem Pharmacol 37:707-713.
34. Romano M, Faggioni R, Sironi M., Sacco S, Echtenacher B, Di Santo E, Salmona M, and Ghezzi P (1997) Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor. Mediators Inflamm 6:32-38.
35. Rucker RB, Romero-Chapman N, Wong T., Lee J, Steinberg FM, McGee C, Clegg M.S., Reiser K., Kosonen T, and Uriu-Hare JY, et al. (1996) Modulation of lysyl oxidase by dietary copper in rats. J Nutr 126:51-60.
36. Salmi M and Jalkanen S (1992) A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 257:1407-1409.
37. Schwelberger HG (2007) The origin of mammalian plasma amine oxidases. J Neural Transm 114:757-762.
38. Stolen CM, Marttila-Ichihara F, Koskinen K., Yegutkin GG, Turja R, Bono P, Skurnik M., Hänninen A, Jalkanen S, and Salmi M (2005) Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 22:105-115.
39. Stolen CM, Yegutkin GG, Kurkijärvi R, Bono P., Alitalo K, and Jalkanen S (2004) Origins of serum semicarbazide-sensitive amine oxidase. Circ Res 95:50-57.
40. Wallin A, Pourazar J, and Sandström T (2004) LPS-induced bronchoalveolar neutrophilia; effects of salmeterol treatment. Respir Med 98:1087-1092.
41. Wang EY, Jones DS, O'Rourke AM, MacDonald MT, Gao H, Ton-Hu, HT, Kessler CA, and Linnick MD (2007) inventors. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for the treatment and prevention of diseases. U.S. patent WO2007120528A2. 2007 Oct 25.
42. Xu HL, Salter-Cid L, Linnik M.D., Wang EY, Paisansathan C, and Pelligrino DA (2006) Vascular adhesion protein-1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia. J Pharmacol Exp Ther 317: 19-29.
43. Yu PH, Lu LX, Fan H, Kazachkov M., Jiang ZJ, Jalkanen S, and Stolen C (2006) Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in lipopolysaccharide-induced pulmonary inflammation. Am J Pathol 168:718-726.
44. Yu PH, Zuo DM, and Davis BA (1994) Characterization of human serum and umbilical artery semicarbazide-sensitive amine oxidase (SSAO). Species heterogeneity and stereoisomeric specificity. Biochem Pharmacol 47:1055-1059.
45. Zhou M, Diwu Z, Panchuk-Voloshina N, and Haugland RP (1997) A stable non-fluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem 253:162-168.
46. Ziaeea M, Rasoulyb M, Khorramib A., Andalibb S, and Garjanib A (2012) The effect of pentoxifylline on leukocyte accumulation and angiogenesis in an air pouch model in rat. J Chem Pharm Res 4:402-408.